These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 2459011)
1. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation? Stürzebecher J; Stürzebecher U Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):152-6. PubMed ID: 2459011 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of serine proteinases by benzamidine derivatives. Walsmann P Acta Biol Med Ger; 1977; 36(11-12):1931-7. PubMed ID: 616739 [TBL] [Abstract][Full Text] [Related]
3. Synthetic inhibitors of bovine factor Xa and thrombin comparison of their anticoagulant efficiency. Stürzebecher J; Stürzebecher U; Vieweg H; Wagner G; Hauptmann J; Markwardt F Thromb Res; 1989 May; 54(3):245-52. PubMed ID: 2749616 [TBL] [Abstract][Full Text] [Related]
4. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants. Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160 [TBL] [Abstract][Full Text] [Related]
7. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin. Katakura S; Nagahara T; Hara T; Iwamoto M Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Hauptmann J; Kaiser B; Nowak G; Stürzebecher J; Markwardt F Thromb Haemost; 1990 Apr; 63(2):220-3. PubMed ID: 2363124 [TBL] [Abstract][Full Text] [Related]
9. Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. Dong H; Chen SX; Kini RM; Xu HX J Nat Prod; 1998 Nov; 61(11):1356-60. PubMed ID: 9834152 [TBL] [Abstract][Full Text] [Related]
10. Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders. De Nanteuil G; Gloanec P; Béguin S; Giesen PL; Hemker HC; Mennecier P; Rupin A; Verbeuren TJ J Med Chem; 2006 Aug; 49(17):5047-50. PubMed ID: 16913694 [TBL] [Abstract][Full Text] [Related]
11. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889 [TBL] [Abstract][Full Text] [Related]
12. Benzamidine derivatives--relationship between antithrombin activity and structure. Walsmann P Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):75-82. PubMed ID: 6177612 [No Abstract] [Full Text] [Related]
13. Tetrahydro-isoquinoline-based factor Xa inhibitors. Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616 [TBL] [Abstract][Full Text] [Related]
14. A comprehensive study on the mechanism of inhibition of serine proteases by benzamidines based on quantitative structure-activity relationship studies. Gupta SP; Handa A; Shewade DG Arzneimittelforschung; 1987 Jan; 37(1):47-50. PubMed ID: 2952126 [TBL] [Abstract][Full Text] [Related]
15. Design of benzamidine-type inhibitors of factor Xa. Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa. Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248 [TBL] [Abstract][Full Text] [Related]
17. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405 [TBL] [Abstract][Full Text] [Related]
18. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022 [TBL] [Abstract][Full Text] [Related]
19. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis. Frank RD; Brandenburg VM; Lanzmich R; Floege J Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159 [TBL] [Abstract][Full Text] [Related]